ESTRO 2024 - Abstract Book

S2649

Clinical - Urology

ESTRO 2024

Fig. 1. Late CTCAE toxicity by time point (months). Grade distribution (%) of (A) genitourinary (GU) and (B) gastrointestinal (GI) toxicity.

Conclusion:

Focal boost SBRT for PCa is associated with encouraging biochemical control rates up to 5-year follow-up in patients with intermediate- and high-risk PCa. Furthermore, prostate SBRT with iso-toxic focal boosting is associated with acceptable late GU and GI toxicity rates.

Keywords: Prostate cancer, SBRT, Focal boost